$18.03
-3.1%Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Chief Human Resources Officer
Chief Medical Officer
Chief Technical Officer
Executive Vice President & Chief Administrative Officer
Compensation
$697,844
Executive Vice President & Chief Commercial Officer
Compensation
$712,029
Executive Vice President & Chief Operating Officer
Compensation
$538,562
Executive Vice President and Chief Strategy & Product Officer
Compensation
$697,844
Executive Vice President, Chief Financial Officer & Treasurer
Compensation
$696,966
Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary
President, Chief Executive Officer & Director
Compensation
$1,393,482
During the last 12 months, insiders have purchased $252K and sold $4K worth of TNDM shares, resulting in $247K of net buying activity.
0
0.00
187
4.31K
-4K
-$4K
0
0.00
2
45.00
-45
-$45
0
0.00
0
0.00
+0
+$0
23.7K
251.72K
0
0.00
+252K
+$252K
Vosseller Leigh
Officer: Evp & Chief Financial Officer
$149K
Sheridan John F
Director, Officer: President & Ceo
$102K
Novara Mark David
Officer: Evp & Chief Commercial Officer
$4K
Strong bullish signal with $247K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
2 insider buyers vs. 1 sellers. More insiders buying than selling indicates positive sentiment.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
TNDM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 07, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 08, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | April 09, 2024 | April 09, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 12, 2023 | April 12, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 13, 2022 | April 13, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 07, 2021 | April 07, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 15, 2020 | March 31, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 11, 2019 | May 22, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 26, 2018 | June 14, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | July 27, 2017 | September 07, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.